Acurx Pharmaceuticals Inc

ACXP

Company Profile

  • Business description

    Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

  • Contact

    259 Liberty Avenue
    Staten IslandNY10305
    USA

    T: +1 917 533-1469

    https://www.acurxpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    4

Stocks News & Analysis

stocks

Guzman Y Gomez’s outlook unchanged despite strong update

Strong quarter yet shares remain expensive.
stocks

Chart of the Week: The warning signs for Aussie banks

Banks enter a lower-growth era.
stocks

3 ASX top picks with wide moats

Wide moat bargains are becoming easier to find.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,840.4028.60-0.32%
CAC 407,915.1542.040.53%
DAX 4025,232.6265.99-0.26%
Dow JONES (US)51,621.4848.62-0.09%
FTSE 10010,831.52106.660.99%
HKSE24,062.72251.45-1.03%
NASDAQ26,692.87511.51-1.88%
Nikkei 22564,425.953,318.34-4.90%
NZX 50 Index13,832.8072.410.53%
S&P 5007,718.940.000.00%
S&P/ASX 2008,719.708.20-0.09%
SSE Composite Index3,707.4859.75-1.59%

Market Movers